关注
Benoît ROUSSEAU
Benoît ROUSSEAU
GI oncology Service, Diaz' Lab, Memorial Sloan Kettering Cancer Center
在 mskcc.org 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer
A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ...
New England Journal of Medicine 386 (25), 2363-2376, 2022
8532022
Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features
J Calderaro, B Rousseau, G Amaddeo, M Mercey, C Charpy, C Costentin, ...
Hepatology 64 (6), 2038-2046, 2016
4252016
Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma
J Calderaro, F Petitprez, E Becht, A Laurent, TZ Hirsch, B Rousseau, ...
Journal of hepatology 70 (1), 58-65, 2019
2742019
Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction
T Simon, S Taleb, N Danchin, L Laurans, B Rousseau, S Cattan, ...
European heart journal 34 (8), 570-577, 2013
2092013
DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity
C Lu, J Guan, S Lu, Q Jin, B Rousseau, T Lu, D Stephens, H Zhang, J Zhu, ...
Cancer cell 39 (1), 96-108. e6, 2021
1852021
The spectrum of benefit from checkpoint blockade in hypermutated tumors
B Rousseau, MB Foote, SB Maron, BH Diplas, S Lu, G Argilés, A Cercek, ...
New England Journal of Medicine 384 (12), 1168-1170, 2021
1682021
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
J Fontugne, J Augustin, A Pujals, P Compagnon, B Rousseau, A Luciani, ...
Oncotarget 8 (15), 24644, 2017
1652017
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity
SX Lu, E De Neef, JD Thomas, E Sabio, B Rousseau, M Gigoux, DA Knorr, ...
Cell 184 (15), 4032-4047. e31, 2021
1622021
Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions
M Hilmi, C Neuzillet, J Calderaro, F Lafdil, JM Pawlotsky, B Rousseau
Journal for immunotherapy of cancer 7, 1-13, 2019
1382019
KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
E Kempf, B Rousseau, B Besse, L Paz-Ares
European respiratory review 25 (139), 71-76, 2016
1102016
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
J Arrondeau, O Mir, P Boudou-Rouquette, R Coriat, S Ropert, G Dumas, ...
Investigational new drugs 30, 2046-2049, 2012
1072012
Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
JM Phelip, D Tougeron, D Léonard, L Benhaim, G Desolneux, A Dupré, ...
Digestive and Liver Disease 51 (10), 1357-1363, 2019
1052019
Alternative Neisseria spp. type IV pilin glycosylation with a glyceramido acetamido trideoxyhexose residue
J Chamot-Rooke, B Rousseau, F Lanternier, G Mikaty, E Mairey, ...
Proceedings of the National Academy of Sciences 104 (37), 14783-14788, 2007
972007
Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study
B Rousseau, P Loulergue, O Mir, A Krivine, S Kotti, E Viel, T Simon, ...
Annals of oncology 23 (2), 450-457, 2012
902012
Immune checkpoint inhibition in colorectal cancer: microsatellite instability and beyond
R Cohen, B Rousseau, J Vidal, R Colle, LA Diaz, T André
Targeted oncology 15, 11-24, 2020
852020
Polymerase proofreading domain mutations: new opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency
R Bourdais, B Rousseau, A Pujals, H Boussion, C Joly, A Guillemin, ...
Critical Reviews in Oncology/Hematology 113, 242-248, 2017
792017
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts
C Neuzillet, O Hentic, B Rousseau, V Rebours, L Bengrine-Lefèvre, ...
World journal of gastroenterology: WJG 18 (33), 4533, 2012
632012
Stage II and stage III colon cancer: treatment advances and future directions
B Rousseau, B Chibaudel, JB Bachet, AK Larsen, C Tournigand, ...
The Cancer Journal 16 (3), 202-209, 2010
512010
CD4 T cell–dependent rejection of beta-2 microglobulin null mismatch repair–deficient tumors
G Germano, S Lu, G Rospo, S Lamba, B Rousseau, S Fanelli, D Stenech, ...
Cancer discovery 11 (7), 1844-1859, 2021
472021
Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC–MS/MS
M Allard, N Khoudour, B Rousseau, C Joly, C Costentin, B Blanchet, ...
Journal of pharmaceutical and biomedical analysis 142, 42-48, 2017
452017
系统目前无法执行此操作,请稍后再试。
文章 1–20